Xeris Biopharma Holdings Overview
Xeris Biopharma Holdings (XERS) has a P/E ratio of -89.6, below the Healthcare sector average of 26.85.
Get informed when a big investor buys or sells
+ Follow-89.60
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Xeris Biopharma Holdings (XERS) currently reports a P/E ratio of -89.6. That is below the Healthcare sector average of 26.85. Use the charts on this page to explore Xeris Biopharma Holdings's P/E ratio history and peer comparisons.
Xeris Biopharma Holdings's P/E ratio of -89.6 is lower than the Healthcare sector average of 26.85. That is roughly 433.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Xeris Biopharma Holdings's market price to a fundamental measure such as earnings, sales, or book value. At -89.6, XERS can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -89.6, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.85. From there, open related valuation or income-statement pages for Xeris Biopharma Holdings, and consider following XERS for alerts when major investors trade the stock.
Xeris Biopharma Holdings is classified in the Healthcare sector. On P/E ratio, it currently shows -89.6 versus a sector average near 26.85. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XERS with unrelated industries.
